Cargando…

Clinical baseline factors predict response to natalizumab: their usefulness in patient selection

BACKGROUND: Optimal patient selection would improve the risk-benefit ratio of natalizumab treatment for relapsing-remitting multiple sclerosis (RR MS). Clinical features of subjects responding to natalizumab have not been univocally recognized. METHODS: Longitudinal data on RR MS patients treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laroni, Alice, Gandoglia, Ilaria, Solaro, Claudio, Ribizzi, Giuseppe, Tassinari, Tiziana, Pizzorno, Matteo, Parodi, Sergio, Baldassarre, Giovanna, Rilla, Maria Teresa, Venturi, Simonetta, Capello, Elisabetta, Sormani, Maria Pia, Uccelli, Antonio, Mancardi, Giovanni Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045962/ https://www.ncbi.nlm.nih.gov/pubmed/24885703 http://dx.doi.org/10.1186/1471-2377-14-103

Ejemplares similares

Teriflunomide treatment reduces B cells in patients with MS
por: Gandoglia, Ilaria, et al.
Publicado: (2017)

Tailoring B cell depletion therapy in MS according to memory B cell monitoring
por: Novi, Giovanni, et al.
Publicado: (2020)

CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis
por: Schiavetti, Irene, et al.
Publicado: (2023)

Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy
por: Godano, Elisabetta, et al.
Publicado: (2021)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Acute disseminated encephalomyelitis with severe neurological outcomes following virosomal seasonal influenza vaccine
por: Alicino, Cristiano, et al.
Publicado: (2014)

Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy
por: Sormani, Maria Pia, et al.
Publicado: (2022)

Quantitative Assessment of Finger Motor Impairment in Multiple Sclerosis
por: Bonzano, Laura, et al.
Publicado: (2013)

CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis
por: Laroni, Alice, et al.
Publicado: (2020)

Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies
por: Sormani, Maria Pia, et al.
Publicado: (2021)

A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients
por: Gugliandolo, Agnese, et al.
Publicado: (2018)

Different MRI patterns in MS worsening after stopping fingolimod
por: Lapucci, Caterina, et al.
Publicado: (2019)

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
por: Novi, Giovanni, et al.
Publicado: (2017)

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
por: Laroni, Alice, et al.
Publicado: (2014)

SARS-COV-2 pandemic impacted on stroke management: The experience of the stroke study group in Liguria (Italy)
por: Gandoglia, Ilaria, et al.
Publicado: (2021)

Natalizumab-induced pneumonitis
por: Kaninia, Stefania, et al.
Publicado: (2021)

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis
por: Uccelli, Antonio, et al.
Publicado: (2019)

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab
por: Toboso, Inmaculada, et al.
Publicado: (2020)

Dalfampridine is associated with de novo occurrence or reoccurrence of positive sensory symptoms in MS
por: Solaro, C., et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
por: Ghezzi, Angelo, et al.
Publicado: (2019)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

Natalizumab in the treatment of Crohn’s disease
por: Guagnozzi, Danila, et al.
Publicado: (2008)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
por: Perkins, Molly R., et al.
Publicado: (2012)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients
por: Iannetta, Marco, et al.
Publicado: (2019)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy
por: Castellazzi, Massimiliano, et al.
Publicado: (2016)

An “all-wheel drive” proposal to accelerate clinical research in common and rare neurological diseases
por: Salvetti, Marco, et al.
Publicado: (2019)

Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
por: Tur, Carmen, et al.
Publicado: (2013)

COVID-19-related and not related Guillain-Barré syndromes share the same management pitfalls during lock down: The experience of Liguria region in Italy
por: Garnero, Martina, et al.
Publicado: (2020)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Pulmonary eosinophilia associated to treatment with natalizumab
por: Curto, Elena, et al.
Publicado: (2016)

Identification of Peptide Mimotope Ligands for Natalizumab
por: Ruff, Laura E., et al.
Publicado: (2018)

Treatment of natalizumab‐associated PML with filgrastim
por: Stefoski, Dusan, et al.
Publicado: (2019)

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

An Italian programme for COVID-19 infection in multiple sclerosis
por: Sormani, Maria Pia
Publicado: (2020)

Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry
por: Prosperini, Luca, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cca4937v21m4sal275e58eil41